SEVERE MULTIFOCAL PLACOID CHORIORETINITIS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITOR THERAPY.

Autor:	Yu JJ; Department of Ophthalmology, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan; and., Everett L; Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon., Sassalos TM; Department of Ophthalmology, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan; and., Johnson MW; Department of Ophthalmology, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan; and.
Jazyk:	angličtina
Zdroj:	Retinal cases & brief reports [Retin Cases Brief Rep] 2024 Jul 01; Vol. 18 (4), pp. 459-463.
DOI:	10.1097/ICB.0000000000001413
Abstrakt:	Purpose: To report a case of severe bilateral multifocal placoid chorioretinitis in a patient receiving ipilimumab and nivolumab therapy for metastatic melanoma. Methods: Retrospective, observational case report. Results: A 31-year-old woman on ipilimumab and nivolumab for metastatic melanoma developed severe multifocal placoid chorioretinitis in both eyes. The patient was started on topical and systemic corticosteroid therapy, and immune checkpoint inhibitor therapy was paused. After resolution of ocular inflammation, the patient was restarted on immune checkpoint inhibitor therapy without return of ocular symptoms. Conclusion: Extensive multifocal placoid chorioretinitis may occur in patients undergoing immune checkpoint inhibitor therapy. Some patients with immune checkpoint inhibitor-related uveitis may successfully resume immune checkpoint inhibitor therapy under close collaboration with the treating oncologist.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu